Treatment of superficial vascular anomalies with topical sirolimus: A multicenter case series.
Administration, Topical
Adolescent
Adult
Child
Child, Preschool
Female
Humans
Immunosuppressive Agents
/ administration & dosage
Infant
Lymphatic Abnormalities
/ drug therapy
Male
Retrospective Studies
Sirolimus
/ administration & dosage
Treatment Outcome
Vascular Malformations
/ drug therapy
Young Adult
genetic diseases/mechanisms
hemangiomas/vascular tumors
therapy topical
vascular malformation
Journal
Pediatric dermatology
ISSN: 1525-1470
Titre abrégé: Pediatr Dermatol
Pays: United States
ID NLM: 8406799
Informations de publication
Date de publication:
Mar 2020
Mar 2020
Historique:
pubmed:
21
1
2020
medline:
2
2
2021
entrez:
21
1
2020
Statut:
ppublish
Résumé
Systemic sirolimus (rapamycin) has recently been found effective in treating complex vascular anomalies by reducing the size and associated complications. Many vascular anomalies have a cutaneous component, and thus, we sought to determine whether topical administration of sirolimus may be an effective therapy, as data on the use of topical sirolimus are limited. We reviewed the efficacy and tolerability of topical formulations of sirolimus in the treatment of various simple and combined vascular malformations and tumors. Eighteen patients with any vascular anomaly treated exclusively with topical sirolimus were retrospectively reviewed. Eleven patients had combined venous lymphatic malformations, three had tufted angiomas, two had a lymphatic malformation, one had a venous malformation, and one had a verrucous venous malformation. All (100%) patients reported some degree of improvement and 50% of patients reported marked improvement in one or more symptoms, most commonly blebs and lymphatic drainage, and bleeding. The retrospective nature, small number of patients, and differences in topical preparations limit the broad application of the results. Topical sirolimus appears to be a safe and useful non-invasive therapy that is well-tolerated in the treatment of the cutaneous portion of a variety of vascular anomalies.
Sections du résumé
BACKGROUND
BACKGROUND
Systemic sirolimus (rapamycin) has recently been found effective in treating complex vascular anomalies by reducing the size and associated complications. Many vascular anomalies have a cutaneous component, and thus, we sought to determine whether topical administration of sirolimus may be an effective therapy, as data on the use of topical sirolimus are limited.
OBJECTIVE
OBJECTIVE
We reviewed the efficacy and tolerability of topical formulations of sirolimus in the treatment of various simple and combined vascular malformations and tumors.
METHODS
METHODS
Eighteen patients with any vascular anomaly treated exclusively with topical sirolimus were retrospectively reviewed.
RESULTS
RESULTS
Eleven patients had combined venous lymphatic malformations, three had tufted angiomas, two had a lymphatic malformation, one had a venous malformation, and one had a verrucous venous malformation. All (100%) patients reported some degree of improvement and 50% of patients reported marked improvement in one or more symptoms, most commonly blebs and lymphatic drainage, and bleeding.
LIMITATIONS
CONCLUSIONS
The retrospective nature, small number of patients, and differences in topical preparations limit the broad application of the results.
CONCLUSION
CONCLUSIONS
Topical sirolimus appears to be a safe and useful non-invasive therapy that is well-tolerated in the treatment of the cutaneous portion of a variety of vascular anomalies.
Substances chimiques
Immunosuppressive Agents
0
Sirolimus
W36ZG6FT64
Types de publication
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
272-277Informations de copyright
© 2020 Wiley Periodicals, Inc.
Références
Azizkhan RG. Complex vascular anomalies. Pediatr Surg Int. 2013;29(10):1023-1038.
Siegel DH, Cottrell CE, Streicher JL, et al. Analyzing the genetic spectrum of vascular anomalies with overgrowth via cancer genomics. J Invest Dermatol. 2018;138:957-967.
Kirkorian AY, Grossberg AL, Püttgen KB. Genetic basis for vascular anomalies. Semin Cutan Med Surg. 2016;35(3):128-136.
Nguyen HL, Bonadurer GF 3rd, Tollefson MM. Vascular malformations and health-related quality of life: a systematic review and meta-analysis. JAMA Dermatol. 2018;154(6):661-669.
Adams DM, Trenor CC 3rd, Hammill AM, et al. Efficacy and safety of sirolimus in the treatment of complicated vascular anomalies. Pediatrics. 2016;137(2):e20153257.
Wiegand S, Wichmann G, Dietz A. Treatment of lymphatic malformations with the mTOR inhibitor sirolimus: a systematic review. Lymphat Res Biol. 2018;16(4):330-339.
Wataya-Kaneda M, Nakamura A, Tanaka M, et al. Efficacy and safety of topical sirolimus therapy for facial angiofibromas in the tuberous sclerosis complex: a randomized clinical trial. JAMA Dermatol. 2017;153(1):39-48.
Le Sage S, David M, Dubois J, et al. Efficacy and absorption of topical sirolimus for the treatment of vascular anomalies in children: a case series. Pediatr Dermatol. 2018;35(4):472-477.
Marqués L, Núñez-Córdoba JM, Aguado L, et al. Topical rapamycin combined with pulsed dye laser in the treatment of capillary vascular malformations in Sturge-Weber syndrome: phase II, randomized, double-blind, intraindividual placebo-controlled clinical trial. J Am Acad Dermatol. 2015;72(1):151-158.e1.
Ivars M, Redondo P. Efficacy of topical sirolimus (rapamycin) for the treatment of microcystic lymphatic malformations. JAMA Dermatol. 2017;153(1):103-105.
Garcia-Montero P, Del Box J, Baselga-Torres E, et al. Use of topical rapamycin in the treatment of lymphatic malformations. J Am Acad Dermatol. 2019;80(2):508-515.
Cai R, Gu H, Yu Z, Yang X, Chen H, Lin X. Topical rapamycin in superficial lymphatic malformation: microcystic lymphatic malformation or verrucous venous malformation?. J Am Acad Dermatol. 2019. pii: S0190-9622(19)30165-3.
Triana P, Dore M, Cerezo VN, et al. Sirolimus in the treatment of vascular anomalies. Eur J Pediatr Surg. 2017;27(1):86-90.
Goines J, Li X, Cai Y, et al. A xenograft model for venous malformation. Angiogenesis. 2018;21(4):725-735.
Murthy AS, Dawson A, Gupta D, Spring S, Cordoro KM. Utility and tolerability of the long-pulsed 1064-nm neodymium:yttrium-aluminum-garnet (LP Nd:YAG) laser for treatment of symptomatic or disfiguring vascular malformations in children and adolescents. J Am Acad Dermatol. 2017;77(3):473-479.
Park J, Yun S-K, Cho Y-S, Song K-H, Kim H-U. Treatment of angiofibromas in tuberous sclerosis complex: the effect of topical rapamycin and concomitant laser therapy. Dermatology. 2014;228(1):37-41.
Wang H, Guo X, Duan Y, Zheng B, Gao Y. Sirolimus as initial therapy for kaposiform hemangioendothelioma and tufted angioma. Pediatr Dermatol. 2018;35(5):635-638.
Kim J, Sun Z, Leraas HJ, et al. Morbidity and healthcare costs of vascular anomalies: a national study. Pediatr Surg Int. 2017;33(2):149-154.